The Medicines Company to Host Cangrelor Webcast on Sunday, March 10, 2013
Conference Call to Be Held at 11:00 a.m. Pacific Time
(firmenpresse) - PARSIPPANY, NJ -- (Marketwire) -- 03/08/13 -- The Medicines Company (NASDAQ: MDCO) has scheduled a conference call and webcast following release of the Phase 3 cangrelor CHAMPION PHOENIX trial results on Sunday, March 10, 2013 at 11:00 a.m. Pacific Time, 2:00 p.m. Eastern Time. MDCO management and experts are scheduled to discuss cangrelor trial results and outlook.
The conference call will be available via phone and webcast. The dial in information is listed below:
Domestic Dial In: 866 700.6067
International Dial In: 617 213.8834
Passcode for both dial in numbers: 54431050
Replay is available from 4:00 p.m. Eastern Time following the conference call through March 17, 2013. To hear a replay of the call, dial 888 286.8010 (domestic) and 617 801.6888 (international). Passcode for both dial in numbers is 17733784.
This call is being webcast and can be accessed at The Medicines Company website at .
The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients. The Medicines Company's website is .
Contact:
Michael Mitchell
The Medicines Company
973-290-6097
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2013 - 09:22 Uhr
Sprache: Deutsch
News-ID 1205021
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PARSIPPANY, NJ
Phone:
Kategorie:
Healthcare
Anmerkungen:
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The Medicines Company to Host Cangrelor Webcast on Sunday, March 10, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Medicines Company (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
